Aviram Daniel, Hikri Daniel, Aharon Michal, Galoz Amir, Lichter Yael, Goder Noam, Nini Asaph, Adi Nimrod, Stavi Dekel
Division of Anesthesia, Pain Management and Intensive Care, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Neurocrit Care. 2025 Apr;42(2):450-456. doi: 10.1007/s12028-024-02105-z. Epub 2024 Sep 19.
The apnea test (AT) plays a vital role in diagnosing brain death by evaluating the absence of spontaneous respiratory activity. It entails disconnecting the patient from mechanical ventilation to raise the CO partial pressure and lower the pH. Occasionally, the AT is aborted because of safety concerns, such as hypoxemia and hemodynamic instability, to prevent worsening conditions. However, the exact oxygen partial pressure level needed before commencing AT, indicating an inability to tolerate the test, is still uncertain. This study seeks to determine pre-AT oxygen levels linked with a heightened risk of test failure.
We conducted a retrospective cohort study involving patients suspected of having brain death at the Tel Aviv Medical Center from 2010 to 2022. The primary outcome was defined as an arterial partial O pressure (PaO) level of 60 mmHg or lower at the conclusion of the AT. This threshold is significant because it marks the point at which the saturation curve deflects, potentially leading to rapid deterioration in the patient's oxygen saturation.
Among the 70 patients who underwent AT, 7 patients met the primary diagnostic criteria. Patients with a PaO ≤ 60 mmHg at the conclusion of the AT exhibited a significantly lower initial median PaO of 243.7 mmHg compared with those with higher pre-AT PaO levels of 374.8 mmHg (interquartile range 104.65-307.00 and interquartile range 267.8-444.9 respectively, P value = 0.0041). Pre-AT PaO levels demonstrated good discriminatory ability for low PaO levels according to the receiver operating characteristic (ROC) curve, with an area under the curve of 0.76 (95% confidence interval 0.52-0.99).
PaO values at the conclusion of the AT are closely associated with PaO values at the beginning of the test. Establishing a cutoff value of approximately 300 mmHg PaO at the onset of AT may assist in avoiding saturation drops below 90%.
呼吸暂停试验(AT)通过评估自主呼吸活动的缺失在脑死亡诊断中起着至关重要的作用。该试验需要将患者与机械通气断开连接,以提高二氧化碳分压并降低pH值。偶尔,由于安全问题,如低氧血症和血流动力学不稳定,为防止病情恶化,AT会中止。然而,开始AT前所需的确切氧分压水平,即表明无法耐受该试验的水平,仍不确定。本研究旨在确定与试验失败风险增加相关的AT前氧水平。
我们进行了一项回顾性队列研究,纳入了2010年至2022年在特拉维夫医疗中心疑似脑死亡的患者。主要结局定义为AT结束时动脉血氧分压(PaO)水平≤60 mmHg。这个阈值很重要,因为它标志着饱和曲线发生偏转的点,可能导致患者血氧饱和度迅速恶化。
在接受AT的70例患者中,7例符合主要诊断标准。AT结束时PaO≤60 mmHg的患者初始中位PaO显著低于AT前PaO水平较高的患者,分别为243.7 mmHg和374.8 mmHg(四分位间距分别为104.65 - 307.00和267.8 - 444.9,P值 = 0.0041)。根据受试者工作特征(ROC)曲线,AT前PaO水平对低PaO水平具有良好的鉴别能力,曲线下面积为0.76(95%置信区间0.52 - 0.99)。
AT结束时的PaO值与试验开始时的PaO值密切相关。在AT开始时设定约300 mmHg PaO的临界值可能有助于避免饱和度降至90%以下。